Covalent targeted radioligands potentiate radionuclide therapyXi‐Yang Cui, Zhu Li, Ziren Kong et al.|Nature|2024Cited by 165
Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical studyGuilan Hu, Li Huo, Zheng Zhang et al.|European Journal of Nuclear Medicine and Molecular Imaging|2022Cited by 39
Publisher Correction: Covalent targeted radioligands potentiate radionuclide therapyXi‐Yang Cui, Zhu Li, Ziren Kong et al.|Nature|2025Cited by 1